The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
It’s ready to jump - breaks to an 2.60 is pretty much next leg up
I’m expecting 2.80/3.00 before any news with the amount of shares in issues doesn’t take a lot to move this.
MC is so undervalued.
Merck Deal knock knock ???
Most the buys last week were recorded as sell.
Imo - I believe we will have news / contract(s) pre Christmas
Thanks Ralphie - i also see Ankyra sign a supply agreement with Regeneron 90 Billion MC
Surely PYC working on the likes of ANK 101 across 2 projects with the data being provided to big hitters in the industry can only be a good thing lol - just wish the company would shout about it alittle more. PR after all....
I see Ankyra and Merck have signed a collaboration and supply agreement for ANK 101 (Well October - I missed this)
PYC worked on ANK101 with Ankyra and were given two contracts !!!
Pfizer and Astellas' XTANDI® Approved by U.S. FDA in Earlier Prostate Cancer Treatment Setting 16th November 2023
Was this what PYC was working on ? The module was never disclosed? I
Not Sure... obviously we have a work relationship with DosemeRx and our software is already integrated into its platform. (This can be seen on the RNS feeds)
Obvs Doseme got sold buy TabulaRasa earlier on in the year... Doseme seems over the past 6 weeks are so publishing a lot of new contracts, integration and being very vocal about the product...
Maybe we are due an update...?
More News
DoseMe Adds Cefepime to Its Model-informed Precision Dosing Platform
HITRUST CSF certified Bayesian dosing platform standardizes dosing mechanisms to optimize antibiotic efficacy in critically ill patients
December 4, 2023
DoseMe, a leading provider of precision dosing software for therapeutic drug monitoring (TDM) and creators of DoseMeRx and DoseMe Analytics, today announced the availability of its Cefepime model. This model will offer pharmacokinetics and target attainment analyses to identify a rational empirical dosing strategy for Cefepime in critically ill patients, including those with unstable renal function, a common challenge faced by clinicians taking care of these complex patients.
Mark Scheetz is a professor at Midwestern University, Chicago College of Pharmacy and holds a joint appointment at Department of Pharmacology, College of Graduate Studies and is the Director of Pharmacometric Center of Excellence at Midwestern University. His research continues to highlight three keys to infectious disease monitoring – real time beta lactam monitoring, therapeutic drug monitoring and precision dosing. “Similar to many beta lactam treatments, Cefepime displays a large amount of variability between patients and having DoseMeRx enables precision dosing,” stated Scheetz. “Pharmacists know when patients’ clearances are changing and they know that creatinine clearance does not capture the drug clearance. It is going to become more prevalent that all drugs need to be monitored.”
The fourth-generation cephalosporin antibiotic is used in the treatment and management of gram-positive and gram-negative bacterial infections. Its most common uses are for pneumonia, skin and soft-tissue infections, complicated intra-abdominal infections, and neutropenic fever. Cefepime is associate with a higher risk of neurotoxicity, particularly in renal dysfunction, as evidenced by a study by Boschung-Pasquier, L. et al. where neurotoxic symptoms were observed in 54% of patients with eGFR 90 mL/min/1.73m2). Utilizing model-informed precision dosing (MIPD) software could minimize this risk.
“As the awareness around suboptimal dosing as a major factor in patient risk increases, DoseMe is at the forefront of innovation,” stated Dr. Sharmeen Roy, PharmD, BCPS, Chief Strategy & Science Officer. “The platform combines smart technology with science leveraging clinically-validated PK/PD models and now pharmacists at healthcare organizations around the globe can dose Cefepime with confidence.”
Therapeutic drug monitoring (TDM) and model-informed precision dosing (MIPD) have evolved as important tools to inform rational dosing of antibiotics in individual patients with infections. In particular, critically ill patients are at the highest risk and often suffer from infections caused by less susceptible bacteria. Greater recognition of the benefits of Model-informed
UTMB Taps DoseMe’s Genetic Biomarker Capabilities for Precision Dosing
Health Science Center to Launch Antibiotic Models for Improved Patient Care; Future Deployment of Wide Range of Models Approved for Rollout
December 6, 2023
DoseMe, a leading provider of precision dosing software for therapeutic drug monitoring and creators of DoseMeRx and DoseMe Analytics, today announced University of Texas Medical Branch (UTMB) will utilize the DoseMe platform to advance its genetic biomarker‐driven precision dosing program.
UTMB set out to address the fact they were not providing enough clinical services based on genomics. “It was not standard practice for the pharmacy to be involved and we knew it was time for a new approach in order to become a precision medical organization,” Akeem Bale, Pharmacy Manager, UMTB PharmD, MS, MBA, BCPS, BCSCP. “The first stage is to focus on providing a pharmacokinetic service for our providers with aminoglycoside and vancomycin AUC/MIC models. The degree of precision these provide is really extraordinary and only the beginning steps for our therapeutic drug modeling initiative.”
In the last decade, genetic biomarker development has facilitated progress in everything from clinical trial design, to precision dosing with unprecedented advances in targeted therapies, immunotherapy and decreased toxicity levels. The dosing of therapeutics must follow this same protocol to improve patient care.
“DoseMe is very excited to partner with UTMB on their long-term, precision strategy that expands well beyond antibiotic models and into oncology, pediatrics and much more,” stated Paul Edwards, CEO of DoseMe. “With over 1.3 million dose calculations made to date, DoseMeRx is the most established Bayesian Dosing Platform on the market, and the feedback from customers like UTMB continues to improve our broad suite of dosing models.”
The only HITRUST CSF certified dosing platform, Doseme is approved by web and IT teams.
UTMB chose to integrate DoseMeRx into the EPIC Electronic Health Records (EHR) for real-time data. It allows agents to quickly and efficiently access and manage critical information, including viewing patient history and medication details, previous contacts, and altering future appointments.
This gives the whole picture of a patient at a glance with historical, current dose and future predicted dosing outcomes. The interface gives customers the ability to edit the data when needed for more accurate, up-to-date patient data.
For the full list of current models for precision dosing, visit https://doseme-rx.com/why-dosemerx/drug-packages.
Totally agree very annoying tbh….100% would put any new investors coming on board imo. Guess that’s the point…..
Irrespective of people’s opinion there is definitely value down here at these prices
Hand held device effectively needed more data - the previous trial at Portsmouth with NICR and NHS showed that taking a lot of blood tests on location were ideal. Granted the dosing app proved to be very effective it needed fine tuning for efficiency - as you would - you wouldn't launch a product at 50% even if you knew and had data to prove it worked.
Beyond blood is a tool that can take blood count at any location in any situation from a hand held device - you link one device and the other you have a very efficient system. The NICR clearly know this as they granting funding . PYC is in a situation whereby the precision side of the dosing tools proves to be effective - with beyond blood data - i have thought they are in a position to get approval by regulators.
PYC / Merck tweet - PYC was effectively retweeting an article about "harnessing mRNA's full potential"
This Trial / Collaboration could be trulley ground breaking to allow people to get blood counts in any setting. Saving loads of time and saving Millions of £ to Healthcare providers - This linked with the precision prostate tool should be truly ground breaking and as the Company have already suggested this could be fast tracked by FDA
Abstract
This application is focused on providing chronically ill patients with a highly convenient and easy way to self monitor the number of white blood cells in their blood during their illness. White blood cells are a vital part of our immune systems and serve as the primary defence against infections in the body by destroying
bacteria, bacterial fragments and viruses in the blood. Low levels of white blood cells in the blood, a condition called neutropenia, is a key indicator that the patient is unwell and a major part of managing conditions such as cancers.
At present white blood cell counts are only possible if the patient visits a clinical facility so that a blood sample can be taken from the arm and then tested in formal laboratory facilities. All immunosuppressed patients need to have this test done frequently to enable them to manage their condition and treatment. Consequently, patients with long term conditions are having to disrupt their day, travel considerable distances, consuming the healthcare system's time in collection of samples and resources to perform these routine blood tests in laboratories. The applicants presenting this application, demonstrated it is possible to integrate new technologies into a simple hand held device that is intelligent enough to count their white blood cells when at home or any convenient location.
The applicants have conducted scientific resea
rch on combining low-cost lasers and computer intelligence (artificial intelligence) such that a computer can automatically "watch and count" the amount of while blood cells in a patient's blood sample. This research has given the team confidence that the method works and can be the basis of a reliable blood count test.
The team's goal now is to research and develop a handheld version of this cell counter, fluid handling system and software such that any user, regardless of their skill level, can obtain a white blood cell count in any setting. The project will focus on the engineering and design work needed to produce the miniaturised system. The team will then use this device to analyse a large collection of blood samples in order to train the algorithm to detect all types of blood cells. Ultimately the project will lead to testing and evaluation of the prototype miniature blood cell counter by a panel of patients and doctors (i.e. primary users of the device in the long term).
So just watched the past company presentation .
I find I weird that after JM explained there is a Million quids plus worth of business in the pipeline and he would update the market obviously on new contracts but then said the company would also update the market if they we trading over expectations then said “say for example 10% over”
I find that very very bizarre. JM isn’t the guy to over promise and under deliver….
My gut feeling especially with the new recruitment is they know the contracts are all but done and it’s greater than the 10% above market expectations.
Why would anyone ever leave themselves exposed like that if they weren’t gonna deliver!!!!
PYC Sharing Merck Tweets today - ohhhhh the Irony.... haaaaaa.
News flow rich season - at this MC no Brainer if you ask me
Doesn't take a rocket scientist to see there is value down here.
As Laura rightly mentions there is news on numerous front as well as the 6 Mill potential from Val that's x3 the current MC
Also doesn't take a rocket scientist to look at the previous RNS feeds to understand historically December is a New heavy month...
Also hopefully just hopefully someone would have realised that the MERCK contracts run in cycles and normally renewed each December
Happy 1st December xxx
With the sheer size of this - I'm confident this will hit international business news - the current largest deposits are in China and Mozambique - EEE Dwarfs there deposits
Get what yours saying.....but to be honest anything at these prices are ridiculous - the whole prospect is HUGE.
Buy and wait....haven't seen anything on this scale ever.... certain we will all be rewarded.
In my view this will rise pretty quickly in the coming sessions when todays news/madness is absorbed i think after 12 is breached it runs from there into high teens. IMO
Good Luck All
I remember that Namibia drill - ridiculous mismanagement
Death Spiral - This Board are Awful
Rinsed people for decades